EA004789B9 - Полимерные конъюгаты бета-1а-интерферона и их использование - Google Patents
Полимерные конъюгаты бета-1а-интерферона и их использованиеInfo
- Publication number
- EA004789B9 EA004789B9 EA200100446A EA200100446A EA004789B9 EA 004789 B9 EA004789 B9 EA 004789B9 EA 200100446 A EA200100446 A EA 200100446A EA 200100446 A EA200100446 A EA 200100446A EA 004789 B9 EA004789 B9 EA 004789B9
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- interferon
- beta
- interferon beta
- polymer conjugates
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/142—Interferon
Abstract
Полипептид бета-интерферона, содержащий бета-1а-интерферон, соединенный с полиалкиленгликолевым фрагментом, где бета-интерферон и полиалкиленгликолевый фрагмент собраны таким образом, что бета-интерферон обладает повышенной активностью относительно других терапевтических форм бета-интерферона (бета-1b-интерферона) и не показывает снижения активности при сравнении с неконъюгированным бета-1а-интерфероном. Конъюгаты данного изобретения удобно применимы как для терапевтического использования, так и для нетерапевтического, например диагностического.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10457298P | 1998-10-16 | 1998-10-16 | |
US12016199P | 1999-02-16 | 1999-02-16 | |
PCT/US1999/024201 WO2000023114A2 (en) | 1998-10-16 | 1999-10-15 | Polymer conjugates of interferon beta- 1a and their uses |
Publications (3)
Publication Number | Publication Date |
---|---|
EA200100446A1 EA200100446A1 (ru) | 2001-10-22 |
EA004789B1 EA004789B1 (ru) | 2004-08-26 |
EA004789B9 true EA004789B9 (ru) | 2017-05-31 |
Family
ID=26801696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200100446A EA004789B9 (ru) | 1998-10-16 | 1999-10-15 | Полимерные конъюгаты бета-1а-интерферона и их использование |
Country Status (30)
Country | Link |
---|---|
US (5) | US6962978B2 (ru) |
EP (4) | EP1656952B1 (ru) |
JP (5) | JP4616478B2 (ru) |
KR (1) | KR100630849B1 (ru) |
CN (2) | CN1329082C (ru) |
AT (1) | ATE318149T1 (ru) |
AU (1) | AU762616B2 (ru) |
BR (1) | BRPI9915542C1 (ru) |
CA (1) | CA2345138C (ru) |
CY (2) | CY1105022T1 (ru) |
CZ (1) | CZ299164B6 (ru) |
DE (1) | DE69930015T2 (ru) |
DK (2) | DK1656952T3 (ru) |
EA (1) | EA004789B9 (ru) |
EE (2) | EE04967B1 (ru) |
ES (4) | ES2653589T3 (ru) |
HK (2) | HK1042434B (ru) |
HU (1) | HU229888B1 (ru) |
IL (2) | IL142282A0 (ru) |
IS (1) | IS2926B (ru) |
LT (2) | LT2599503T (ru) |
NO (1) | NO20011860L (ru) |
NZ (1) | NZ510689A (ru) |
PL (1) | PL206536B1 (ru) |
PT (2) | PT1121156E (ru) |
SG (2) | SG110047A1 (ru) |
SI (2) | SI1656952T1 (ru) |
SK (1) | SK287918B6 (ru) |
TR (1) | TR200101086T2 (ru) |
WO (1) | WO2000023114A2 (ru) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK287918B6 (sk) * | 1998-10-16 | 2012-03-02 | Biogen Idec Ma Inc. | Composition containing glycosylated interferon-beta-1a, pharmaceutical composition, use of composition, in-vitro method of prolonging the activity of interferon-beta-1a and use of polymer moiety |
SK287491B6 (sk) * | 1998-10-16 | 2010-11-08 | Biogen Idec Ma Inc. | Fúzne proteíny interferónu- beta-1a a ich použitie |
US7431921B2 (en) | 2000-04-14 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
JP2003527090A (ja) * | 1999-08-27 | 2003-09-16 | マキシゲン・エイピーエス | 新規なインターフェロンベータ様分子 |
US7144574B2 (en) | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
EP1334128A2 (en) * | 2000-11-02 | 2003-08-13 | Maxygen Aps | New multimeric interferon beta polypeptides |
IL156059A0 (en) | 2001-02-27 | 2003-12-23 | Maxygen Aps | NEW INTERFERON beta-LIKE MOLECULES |
US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
ES2538342T3 (es) | 2001-10-10 | 2015-06-19 | Ratiopharm Gmbh | Remodelación y glicoconjugación de la hormona estimuladora del folículo (FSH) |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
AU2004236174B2 (en) | 2001-10-10 | 2011-06-02 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
UA82184C2 (ru) * | 2002-01-18 | 2008-03-25 | Байоджин Айдек Ма Инк. | Полиалкиленгликоль с остатком для конъюгации биологически активного соединения |
AU2003254641A1 (en) * | 2002-08-28 | 2004-03-19 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
AU2003263552A1 (en) * | 2002-09-09 | 2004-03-29 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
DK1575531T3 (da) * | 2002-09-27 | 2011-11-21 | Biogen Idec Inc | Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta |
US20040062748A1 (en) * | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
AU2003303635B2 (en) | 2002-12-26 | 2009-07-23 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
WO2004060300A2 (en) * | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
BRPI0408358A (pt) | 2003-03-14 | 2006-03-21 | Neose Technologies Inc | polìmeros hidrossolúveis ramificados e seus conjugados |
WO2004084949A2 (en) * | 2003-03-20 | 2004-10-07 | Xencor | Generating protein pro-drugs using reversible ppg linkages |
JP2006521372A (ja) * | 2003-03-28 | 2006-09-21 | バイオポリメド インコーポレーテッド | 生物学的活性物質と生体適合性高分子の1:1接合体、この製造方法とこれを含む薬学組成物 |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
US7691603B2 (en) | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
US20070072303A1 (en) * | 2003-05-21 | 2007-03-29 | Ares Trading S.A. | Method of chromatographic analysis of a protein solution |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
EP1666496B1 (en) | 2003-08-25 | 2014-03-12 | Toray Industries, Inc. | Interferon-beta composite |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
JP5743368B2 (ja) | 2004-01-08 | 2015-07-01 | ラショファーム ゲーエムベーハー | ペプチドのo結合型グリコシル化 |
AU2005211362B2 (en) * | 2004-02-02 | 2008-03-13 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
WO2005084303A2 (en) * | 2004-03-01 | 2005-09-15 | Enzon Pharmaceuticals, Inc. | Interferon-beta polymer conjugates |
WO2005112911A2 (en) * | 2004-05-21 | 2005-12-01 | The Regents Of The University Of California | Compositions and methods for treating myelin deficiency disorders |
EP1771197A2 (en) * | 2004-06-30 | 2007-04-11 | Egen Corporation | Pegylated interferon alpha-1b |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
EP3061461A1 (en) | 2004-10-29 | 2016-08-31 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
JP4951527B2 (ja) | 2005-01-10 | 2012-06-13 | バイオジェネリックス アーゲー | 糖peg化顆粒球コロニー刺激因子 |
WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
JP5216580B2 (ja) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー/エス | グリコペグ化第ix因子 |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
JP2009514814A (ja) * | 2005-10-21 | 2009-04-09 | シナジェバ・バイオファーマ・コーポレイション | グリコール化およびグリコシル化された家禽類由来の治療用たんぱく質 |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
EP1951285A2 (en) * | 2005-11-18 | 2008-08-06 | Ares Trading S.A. | Interferon in influenza |
CN101384272B (zh) | 2005-12-20 | 2013-05-01 | 杜克大学 | 用于递送具有增强的药理性质的活性剂的方法和组合物 |
CN100475270C (zh) * | 2006-01-20 | 2009-04-08 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
US20080038224A1 (en) * | 2006-03-28 | 2008-02-14 | Thierry Guyon | Modified interferon-beta (IFN-beta) polypeptides |
US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
EP2010222A1 (en) | 2006-03-31 | 2009-01-07 | Baxter International Inc. | Pegylated factor viii |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
US8637325B2 (en) * | 2009-02-16 | 2014-01-28 | University Of Wyoming | Method and apparatus for pyrolysis-induced cleavage in peptides and proteins |
JP2009544327A (ja) | 2006-07-21 | 2009-12-17 | ノヴォ ノルディスク アー/エス | O−結合型グリコシル化配列によるペプチドのグリコシル化 |
EP2059527B1 (en) | 2006-09-01 | 2014-12-03 | Novo Nordisk Health Care AG | Modified glycoproteins |
JP2010503630A (ja) * | 2006-09-15 | 2010-02-04 | クレアビリス・セラピューティクス・エスピーエー | HMGB1のBox−AおよびHMGB1のBox−A変異体のポリマー複合体 |
JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー/エス | ポリペプチドコンジュゲートの精製方法 |
EP2101821B1 (en) | 2006-12-15 | 2014-08-13 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
AU2007338771A1 (en) * | 2006-12-19 | 2008-07-03 | Merrimack Pharmaceuticals, Inc. | Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis |
ES2406267T3 (es) | 2007-04-03 | 2013-06-06 | Biogenerix Ag | Métodos de tratamiento usando G-CSF glicopegilado |
US8114630B2 (en) | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
CN101778859B (zh) | 2007-06-12 | 2014-03-26 | 诺和诺德公司 | 改良的用于生产核苷酸糖的方法 |
WO2009047500A1 (en) * | 2007-10-09 | 2009-04-16 | Polytherics Limited | Novel conjugated proteins and peptides |
WO2009080699A2 (en) | 2007-12-20 | 2009-07-02 | Merck Serono S.A. | Peg-interferon-beta formulations |
NZ586947A (en) | 2008-02-08 | 2012-11-30 | Ambrx Inc | Modified leptin polypeptides and their uses |
ES2476690T3 (es) | 2008-02-27 | 2014-07-15 | Novo Nordisk A/S | Moléculas conjugadas del Factor VIII |
EP2288715B1 (en) | 2008-04-11 | 2014-09-24 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
CA2721870C (en) | 2008-04-21 | 2020-12-22 | Tissue Regeneration Therapeutics, Inc. | Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |
US10138283B2 (en) | 2008-07-23 | 2018-11-27 | Ambrx, Inc. | Modified bovine G-CSF polypeptides and their uses |
US8927694B2 (en) | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
GB0912485D0 (en) * | 2009-07-17 | 2009-08-26 | Polytherics Ltd | Improved conjugation method |
AU2010242905B2 (en) * | 2009-04-30 | 2014-10-23 | Children's Hospital & Research Center At Oakland | Chimeric factor H binding proteins (fHbp) and methods of use |
WO2010142017A1 (en) | 2009-06-09 | 2010-12-16 | Defyrus, Inc . | Administration of interferon for prophylaxis against or treatment of pathogenic infection |
ES2597954T3 (es) | 2009-07-27 | 2017-01-24 | Baxalta GmbH | Conjugados de proteína de la coagulación sanguínea |
CN102573920B (zh) | 2009-07-27 | 2015-01-14 | 利普森技术有限公司 | 非凝血蛋白的糖基多唾液酸化 |
HUE028056T2 (en) | 2009-07-27 | 2016-11-28 | Baxalta GmbH | Blood coagulation protein conjugates |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
CN107056929A (zh) | 2009-12-21 | 2017-08-18 | Ambrx 公司 | 经过修饰的猪促生长素多肽和其用途 |
NZ600361A (en) | 2009-12-21 | 2014-06-27 | Ambrx Inc | Modified bovine somatotropin polypeptides and their uses |
CN101906213B (zh) * | 2010-07-23 | 2012-12-05 | 华南理工大学 | 一种新型的蛋白质糖基化接枝的方法 |
EP2606072A4 (en) * | 2010-08-19 | 2016-04-20 | Peg Biosciences Inc | SYNERGISTIC BIOMOLECULAR POLYMER CONJUGATES |
TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
CA2813304A1 (en) * | 2010-10-01 | 2012-04-05 | Biogen Idec Ma Inc. | Interferon-beta for use as monotherapy or in combination with other cancer therapies |
NZ612320A (en) | 2010-12-22 | 2015-06-26 | Baxter Healthcare Sa | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
RU2636456C2 (ru) | 2011-10-01 | 2017-11-23 | Глитек, Инк. | Гликозилированный полипептид и содержащая его фармацевтическая композиция |
US20150030564A1 (en) | 2012-02-29 | 2015-01-29 | Toray Industries, Inc. | Inhibitory agent for body cavity fluid accumulation |
WO2014036520A1 (en) | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
DK2982686T3 (en) | 2013-03-29 | 2018-10-08 | Glytech Inc | POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED |
WO2016013911A1 (ko) | 2014-07-24 | 2016-01-28 | 에이비온 주식회사 | 페길화된 인터페론 -베타 변이체 |
EP3454887B1 (en) | 2016-05-13 | 2021-01-20 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
WO2018141964A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences Nv | Targeted chimeric proteins and uses thereof |
RU2661088C1 (ru) * | 2017-05-24 | 2018-07-11 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона бета 1b для лечения рассеянного склероза |
KR20200128533A (ko) | 2018-02-05 | 2020-11-13 | 오리오니스 바이오사이언시즈 인코포레이티드 | 섬유아세포 결합제 및 이의 용도 |
RU2739261C1 (ru) * | 2019-12-31 | 2020-12-22 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ количественного определения антипролиферативной активности интерферона-бета человека |
CN117321087A (zh) | 2021-03-26 | 2023-12-29 | 先天制药公司 | 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质 |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
CA3218793A1 (en) | 2021-06-09 | 2022-12-15 | Laurent Gauthier | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DE2360794C2 (de) * | 1973-12-06 | 1984-12-06 | Hoechst Ag, 6230 Frankfurt | Verfahren zur Herstellung von Peptiden |
CH596313A5 (ru) * | 1975-05-30 | 1978-03-15 | Battelle Memorial Institute | |
IL47468A (en) | 1975-06-12 | 1979-05-31 | Rehovot Res Prod | Process for the cross-linking of proteins using water soluble cross-linking agents |
US4002531A (en) * | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4456748A (en) | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
DE3273787D1 (en) | 1981-02-04 | 1986-11-20 | Japan Found Cancer | Human interferon-beta gene |
US4414147A (en) * | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
IT1167610B (it) | 1982-01-19 | 1987-05-13 | Cetus Corp | Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione |
US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
US4695543A (en) | 1982-03-23 | 1987-09-22 | Bristol-Myers Company | Alpha Interferon GX-1 |
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
US4470461A (en) | 1982-09-30 | 1984-09-11 | Phillips Petroleum Company | Organic nitro compounds as cosurfactants in enhanced oil recovery processes |
US4588585A (en) * | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
GB8334102D0 (en) | 1983-12-21 | 1984-02-01 | Searle & Co | Interferons with cysteine pattern |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
GB8412564D0 (en) * | 1984-05-17 | 1984-06-20 | Searle & Co | Structure and properties |
CA1302320C (en) | 1984-06-11 | 1992-06-02 | Hideo Niwa | Expression of human cromosomal interferon-_ in animal cells |
US5231176A (en) | 1984-08-27 | 1993-07-27 | Genentech, Inc. | Distinct family DNA encoding of human leukocyte interferons |
FI90990C (fi) | 1984-12-18 | 1994-04-25 | Boehringer Ingelheim Int | Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi |
US4885166A (en) | 1985-06-11 | 1989-12-05 | Ciba-Geigy Corporation | Hybrid interferons |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
EP0229108B1 (en) | 1985-06-26 | 1990-12-27 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
JPS63152393A (ja) | 1986-07-03 | 1988-06-24 | Takeda Chem Ind Ltd | グリコシル誘導体 |
US5183746A (en) | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
US4894226A (en) | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
US5004605A (en) | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5135919A (en) | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US4847625A (en) * | 1988-02-16 | 1989-07-11 | Ford Aerospace Corporation | Wideband, aperture-coupled microstrip antenna |
CA1340810C (en) | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
AU4660789A (en) | 1988-11-23 | 1990-06-12 | Genentech Inc. | Polypeptide derivatives |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
US5286637A (en) | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
CA2106079C (en) | 1991-03-15 | 2000-04-25 | Robert C. Thompson | Pegylation of polypeptides |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
WO1993000109A1 (en) | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
WO1993012145A1 (en) * | 1991-12-19 | 1993-06-24 | Baylor College Of Medicine | Pva or peg conjugates of peptides for epitope-specific immunosuppression |
ZA933926B (en) * | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
AU5098193A (en) | 1992-09-01 | 1994-03-29 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
US5306344A (en) * | 1992-12-02 | 1994-04-26 | Edward C. Levy Company | Mixture of portland cement concrete materials for freeze/thaw resistance |
US5298410A (en) | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5874075A (en) | 1993-10-06 | 1999-02-23 | Amgen Inc. | Stable protein: phospholipid compositions and methods |
US5641656A (en) | 1993-10-22 | 1997-06-24 | University Of Connecticut | Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
ES2174915T3 (es) * | 1993-11-10 | 2002-11-16 | Enzon Inc | Productos de conjugacion mejorados de un interferon con un polimero. |
US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
WO1995021629A1 (en) | 1994-02-08 | 1995-08-17 | Amgen Inc. | Oral delivery of chemically modified proteins |
US5545723A (en) * | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
GB9415379D0 (en) * | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
CA2206852A1 (en) * | 1994-12-07 | 1996-06-13 | Novo Nordisk A/S | Polypeptide with reduced allergenicity |
US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US5702717A (en) | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US5747639A (en) * | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
ATE200030T1 (de) | 1997-01-29 | 2001-04-15 | Polymasc Pharmaceuticals Plc | Pegylationsverfahren |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
EP1012184B1 (en) | 1997-07-14 | 2007-10-10 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
US6180095B1 (en) | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
US5965119A (en) | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
WO1999045964A1 (en) | 1998-03-12 | 1999-09-16 | Shearwater Polymers, Incorporated | Poly(ethylene glycol) derivatives with proximal reactive groups |
NZ507456A (en) * | 1998-04-28 | 2003-10-31 | Applied Research Systems | Process and conjugated forms of PEGylated interferon- beta with polyethylene glycol (PEG) wherein the thiol reactive polyol agent is mono-methoxylated |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
SK287491B6 (sk) * | 1998-10-16 | 2010-11-08 | Biogen Idec Ma Inc. | Fúzne proteíny interferónu- beta-1a a ich použitie |
SK287918B6 (sk) * | 1998-10-16 | 2012-03-02 | Biogen Idec Ma Inc. | Composition containing glycosylated interferon-beta-1a, pharmaceutical composition, use of composition, in-vitro method of prolonging the activity of interferon-beta-1a and use of polymer moiety |
US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
US7144574B2 (en) | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
JP2003527090A (ja) * | 1999-08-27 | 2003-09-16 | マキシゲン・エイピーエス | 新規なインターフェロンベータ様分子 |
AU781839B2 (en) | 1999-12-22 | 2005-06-16 | Nektar Therapeutics | Sterically hindered derivatives of water soluble polymers |
US9506008B2 (en) | 2013-12-23 | 2016-11-29 | Exxonmobil Research And Engineering Company | Method for improving engine fuel efficiency |
-
1999
- 1999-10-15 SK SK506-2001A patent/SK287918B6/sk not_active IP Right Cessation
- 1999-10-15 ES ES10182477.9T patent/ES2653589T3/es not_active Expired - Lifetime
- 1999-10-15 ES ES06003415.4T patent/ES2447772T3/es not_active Expired - Lifetime
- 1999-10-15 LT LTEP12198907.3T patent/LT2599503T/lt unknown
- 1999-10-15 NZ NZ510689A patent/NZ510689A/en not_active IP Right Cessation
- 1999-10-15 SI SI9931074T patent/SI1656952T1/sl unknown
- 1999-10-15 PT PT99970609T patent/PT1121156E/pt unknown
- 1999-10-15 IL IL14228299A patent/IL142282A0/xx active IP Right Grant
- 1999-10-15 ES ES99970609T patent/ES2257884T3/es not_active Expired - Lifetime
- 1999-10-15 CZ CZ20011329A patent/CZ299164B6/cs not_active IP Right Cessation
- 1999-10-15 WO PCT/US1999/024201 patent/WO2000023114A2/en active IP Right Grant
- 1999-10-15 AU AU14465/00A patent/AU762616B2/en active Active
- 1999-10-15 BR BRPI9915542A patent/BRPI9915542C1/pt not_active IP Right Cessation
- 1999-10-15 TR TR2001/01086T patent/TR200101086T2/xx unknown
- 1999-10-15 JP JP2000576887A patent/JP4616478B2/ja not_active Expired - Lifetime
- 1999-10-15 SG SG200302608A patent/SG110047A1/en unknown
- 1999-10-15 SG SG2008070138A patent/SG2008070138A/en unknown
- 1999-10-15 SI SI9930890T patent/SI1121156T1/sl unknown
- 1999-10-15 DE DE69930015T patent/DE69930015T2/de not_active Expired - Lifetime
- 1999-10-15 EA EA200100446A patent/EA004789B9/ru not_active IP Right Cessation
- 1999-10-15 EP EP06003415.4A patent/EP1656952B1/en not_active Expired - Lifetime
- 1999-10-15 PL PL347968A patent/PL206536B1/pl not_active IP Right Cessation
- 1999-10-15 PT PT60034154T patent/PT1656952E/pt unknown
- 1999-10-15 EP EP99970609A patent/EP1121156B1/en not_active Expired - Lifetime
- 1999-10-15 KR KR1020017004800A patent/KR100630849B1/ko active Protection Beyond IP Right Term
- 1999-10-15 EP EP10182477.9A patent/EP2260872B1/en not_active Expired - Lifetime
- 1999-10-15 CN CNB998122025A patent/CN1329082C/zh not_active Expired - Lifetime
- 1999-10-15 EP EP12198907.3A patent/EP2599503B1/en not_active Expired - Lifetime
- 1999-10-15 DK DK06003415.4T patent/DK1656952T3/da active
- 1999-10-15 ES ES12198907.3T patent/ES2630278T3/es not_active Expired - Lifetime
- 1999-10-15 CN CN200710112119.8A patent/CN101062419B/zh not_active Expired - Lifetime
- 1999-10-15 HU HU0200444A patent/HU229888B1/hu unknown
- 1999-10-15 EE EEP200100220A patent/EE04967B1/xx unknown
- 1999-10-15 CA CA002345138A patent/CA2345138C/en not_active Expired - Lifetime
- 1999-10-15 AT AT99970609T patent/ATE318149T1/de active
- 1999-10-15 DK DK99970609T patent/DK1121156T3/da active
- 1999-10-15 EE EEP200700058A patent/EE05201B1/xx unknown
-
2001
- 2001-03-27 IL IL142282A patent/IL142282A/en active Protection Beyond IP Right Term
- 2001-03-30 IS IS5913A patent/IS2926B/is unknown
- 2001-04-11 NO NO20011860A patent/NO20011860L/no not_active Application Discontinuation
- 2001-04-11 US US09/832,658 patent/US6962978B2/en not_active Expired - Lifetime
-
2002
- 2002-05-21 HK HK02103771.7A patent/HK1042434B/zh not_active IP Right Cessation
-
2004
- 2004-03-16 US US10/802,540 patent/US7446173B2/en not_active Expired - Lifetime
-
2006
- 2006-05-02 CY CY20061100568T patent/CY1105022T1/el unknown
- 2006-10-12 JP JP2006279334A patent/JP2007063283A/ja active Pending
- 2006-10-16 HK HK06111314.0A patent/HK1089393A1/xx not_active IP Right Cessation
-
2008
- 2008-03-20 US US12/077,605 patent/US20090104150A1/en not_active Abandoned
-
2010
- 2010-09-14 JP JP2010206172A patent/JP5396358B2/ja not_active Expired - Lifetime
-
2011
- 2011-02-10 JP JP2011027941A patent/JP2011093937A/ja not_active Withdrawn
-
2012
- 2012-08-16 US US13/587,242 patent/US9314534B2/en not_active Expired - Lifetime
-
2014
- 2014-03-14 CY CY20141100207T patent/CY1115125T1/el unknown
- 2014-03-26 JP JP2014064230A patent/JP5863865B2/ja not_active Expired - Lifetime
-
2016
- 2016-04-18 US US15/131,233 patent/US20160250340A1/en not_active Abandoned
-
2017
- 2017-10-05 LT LTPA2017030C patent/LTC2599503I2/lt unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA004789B9 (ru) | Полимерные конъюгаты бета-1а-интерферона и их использование | |
BG101540A (en) | Interferon conjugates | |
PL371781A1 (en) | G-csf conjugates | |
IL109619A (en) | Conjugation-stabilized polypeptide compositions and therapeutic and diagnostic formulations comprising same | |
BG103968A (en) | Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity | |
SG149685A1 (en) | Polymer conjugates of neublastin and methods of using same | |
IL106591A0 (en) | An interferon alpha/beta binding protein,its preparation and pharmaceutical compositions containing it | |
UA29639A (ru) | Противоопухолевое средство | |
PL345267A1 (en) | Recombinant human interferon beta-1a (ifn-beta-1a) formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TC4A | Change in name of a patent proprietor in a eurasian patent |
Designated state(s): AM AZ KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ KZ KG TJ TM |
|
TC4A | Change in name of a patent proprietor in a eurasian patent | ||
ND4A | Extension of term of a eurasian patent | ||
TH4A | Publication of the corrected specification to eurasian patent | ||
MK4A | Patent expired |
Designated state(s): AM BY MD |